ICER releases draft evidence report on therapies for sickle cell disease

23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...

Read more →

ICER releases evidence report on acute treatments for migraine

10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...

Read more →

ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis

9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...

Read more →

ICER posts draft scoping document for the assessment of treatments for beta thalassaemia

6 January 2020 - Document open to public comment until 27 January 2020. ...

Read more →

ICER to assess gene therapy for haemophilia A

3 January 2020 - Report will be subject of New England CEPAC meeting in August 2020; open Input now being accepted ...

Read more →

Expanding use of multi-criteria decision analysis for health technology assessment

11 December 2019 - As America’s health care system continues to evolve, it is critical that our perception of care ...

Read more →

ICER issues final report and policy recommendations for add-on therapies to treat type 2 diabetes

9 December 2019 - Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin. ...

Read more →

ICER to assess gene therapy for beta thalassaemia

5 December 2019 - Report will be subject of New England CEPAC meeting in July 2020; open Input now being accepted ...

Read more →

Does the Institute for Clinical and Economic Review revise its findings in response to industry comments?

2 December 2019 - The ICER has gained prominence through its work conducting health technology assessments of pharmaceuticals in the United ...

Read more →

ICER releases evidence report on JAK inhibitors to treat rheumatoid arthritis

26 November 2019 - Using adalimumab as the comparator, upadacitinib’s value-based price benchmark is between $44,000-$45,000 per year; at December 9 ...

Read more →

ICER opens nominations for new members of its voting panels

25 November 2019 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...

Read more →

ICER seeks public input to guide selection of non-drug assessment topics for 2020

13 December 2019 - Suggestions for new topics and comments on initial list of potential topics are encouraged; input most helpful ...

Read more →

ICER finalises method adaptations for assessing potential cures and other high-impact single or short-term therapies

12 November 2019 - Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic ...

Read more →

ICER releases draft evidence report on acute migraine therapies

7 November 2019 - Public comment period on preliminary draft now open until 6 December 2019; requests to make oral comment ...

Read more →

Obscure model puts a price on good health—and drives down drug costs

4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...

Read more →